The bill amends the "Right to Try Act" to enhance access to experimental treatments for patients with advanced, life-threatening, or severely debilitating illnesses. It introduces new definitions and clarifications, including the terms "individualized investigational treatment" and "life-threatening or severely debilitating illness." The bill specifies that eligible patients must have an advanced illness, have considered all other treatment options, and provide informed consent for the use of investigational drugs, biological products, or devices. Additionally, it establishes that manufacturers may provide these treatments without compensation or require patients to cover associated costs.

The legislation also protects healthcare providers from sanctions for recommending or providing access to investigational treatments and prohibits state officials from obstructing patient access to these treatments. It clarifies that insurers are not mandated to cover the costs associated with these investigational treatments, nor are they required to provide new services unless approved. Furthermore, the bill ensures that if a patient dies while receiving such treatment, their heirs are not liable for any related debts. Overall, the bill aims to facilitate patient access to potentially life-saving experimental therapies while providing legal protections for both patients and healthcare providers.

Statutes affected:
House Introduced Bill: 333.26451